Evidence map›Paper›PMID 37593813›Full record

ArticleJournal of gynecologic oncology2023

FIGO staging of endometrial cancer: 2023.

Jonathan S Berek, Xavier Matias-Guiu, Carien Creutzberg, Christina Fotopoulou, David Gaffney, Sean Kehoe, Kristina Lindemann, David Mutch, Nicole Concin, Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
157citing papers in PubMed, 8 pooled it
65.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

157 citing papers in PubMed, 8 syntheses or guidelines pooled it, 223 citations in OpenAlex.

  1. FIGO staging for gestational trophoblastic neoplasia: 2026.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. AKR1B1 and AKR1B10 as Potential Prognostic Biomarkers of Endometrial Cancer.International journal of molecular sciences · 2026
    Article
  18. Article
  19. Article
  20. Article

97 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 7 countries.

Jonathan S BerekStanford University School of Medicine, Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford, CA, USA. jberek@stanford.edu.ORCID 0000-0002-8734-1961
Xavier Matias-GuiuDepartment of Pathology, Hospital U de Bellvitge and Hospital U Arnau de Vilanova, Universities of Lleida and Barcelona, Institut de Recerca Biomèdica de Lleida, Instituto de Investigación Biomédica de Bellvitge, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain.ORCID 0000-0002-7201-6605
Carien CreutzbergDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-7008-4321
Christina FotopoulouGynaecological Oncology, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0001-6375-9645
David GaffneyDepartment of Radiation Oncology, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-5752-1611
Sean KehoeOxford Gynaecological Cancer Centre, Churchill Hospital, Oxford, UK.ORCID 0000-0003-3830-9532
Kristina LindemannDepartment of Gynaecological Cancer, Oslo University Hospital, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0002-2162-0175
David MutchDivision of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-6921-1581
Nicole ConcinDepartment of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-9795-2643
Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee
Cancer Prevention Institute of California · USInstituto de Investigación Biomédica de Lleida · ESInternational Federation of Gynaecology and Obstetrics · GBLeiden University Medical Center · NLOslo University Hospital · NOUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMany advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies.

methodsThe FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system.

resultsBased on the existing evidence, the substages were defined as follows: SUMMARY: The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsPeritoneal NeoplasmsEndometriumFemaleHumansUterusCancer StagingEndometrial CancerEndometrial Cancer Molecular StagingFIGO Cancer StagingFIGO Endometrial Cancer Staging

Identifiers

PMID37593813
PMCPMC10482588
OpenAlexW4385816805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.